sildenafil-citrate and Hyperlipidemias

Erectile dysfunction (ED) has been associated with several comorbidities and can cause significant loss of quality of life and self-esteem.. In men with ED, to use the validated Self-Esteem and Relationship (SEAR) questionnaire to evaluate changes in self-esteem associated with sildenafil treatment of ED and to assess changes dependent on concomitant comorbid conditions.. This was a 14-week, international, randomized, parallel-group, double-blind, flexible-dose (25, 50, or 100 mg), placebo-controlled study of sildenafil in men aged >or=18 years with a clinical diagnosis of ED (score

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder; Double-Blind Method; Erectile Dysfunction; Expressed Emotion; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quality of Life; Self Concept; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Young Adult

The aim of the present study was to elucidate the possible biochemical alterations in lipid metabolic profile and organ function profiles that may result from continuous treatment with the drug, sildenafil in normal and hyperlipidemic rats. Blood samples were taken for biochemical analysis on days 30, 45 and 60 of the experiment. Sildenafil (5.625 mg/kg) significantly decreased the serum lipid parameters including total lipid, triacylglycerols, cholesterol, HDL-C, LDL-C, VLDL-C concentrations of rats fed on fat-enriched diet. However, it increased their values in serum of negative control rats. In addition, administration of sildenafil to normal rats caused insignificant changes in serum liver enzymes ALT and AST concentrations all over the period of the experiment; as well as serum urea and creatinine; yet, it significantly decreased their serum concentrations in animals fed on fat-enriched diet compared to the +ve untreated ones, upon its administration starting from the 30th day of the experiment.However, concurrent administration of sildenafil with highfat diet (group-iv) failed to guard against the rise in such liver and kidney function biomarkers. These data suggest that sildenafil may act as a mixed blessing drug; therefore it must be used carefully and under physician supervision to get its therapeutic benefits and guard against its adverse effects.

Topics: Animals; Hyperlipidemias; Lipids; Liver; Rats; Rats, Wistar; Sildenafil Citrate

To find the factors linked to erectile dysfunction, to evaluate this as a possible marker of health status, to analyse the evolution of clinical parameters of associated illnesses and the response to Viagra.Design. Intervention study without a control.. Alguazas Health Centre (Murcia).. All the patients in the programme (125), with a figure on the sexual health in men index (SHIM) below 21.Interventions. Health education and administration of Viagra.. Concomitant illnesses, pathologies previously unknown to the patient, changes in erectile function valued on the international index of erectile function (IIEF), and changes in blood pressure, glucaemia and lipids.. Factors linked to erectile dysfunction were diabetes (50.4%), hypertension (33.6%), hypercholesterolaemia (22.4%), urological pathology (12.8%) and mental health disorders (33.6%). The hidden pathology detected was 15 cases of hypertension, 3 diabetes, 2 cardiopathies, 20 dyslipaemias, 3 depressions, 13 anxiety and 5 urological problems. The variations in clinical parameters at 3 months were: glucaemia, -38.3 mg (P<.001, Student s t=-5.186); HbA1c, -0.9 (P<.05, Student s t=-2.16); systolic blood pressure, -16 mm Hg (P<.01, Student s t=-3.486) and diastolic pressure -13 mm Hg (P<.001, Student s t=-4.594); and total cholesterol, -14.2% (P<.001, Student s t=7.01). Erectile function improved by 74% with Viagra.. 2 out of every 3 patients with erectile dysfunction presented associated diseases; one in every 3 were ignorant of their health problem. Monitoring of chronic illnesses improved significantly. Finally, 3 in every 4 responded to Viagra.

Topics: Adult; Age Factors; Aged; Anxiety; Data Interpretation, Statistical; Depression; Diabetes Complications; Erectile Dysfunction; Health Status; Heart Diseases; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Factors; Sildenafil Citrate; Sulfones; Urologic Diseases; Vasodilator Agents